

References

1. Stewart GJ, Ashton LJ, Biti RA, et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non progressor with HIV-1 infection. *AIDS* 1997, 11:1833-1838.
2. Mendila M, Heiken H, Becker S, et al. Immunologic and Virologic studies in long-term non progressor with HIV-1 infection. *Eur J Med Res* 1999, 4:417-424.
3. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 in highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. *Proc Natl Acad Sci USA* 2000, 97:2709-2714.
4. Mosier DE. CD4+ cell turnover [letter]. *Nature* 1995, 375:193-194.
5. Sprent J, Toughh D. CD4+ cell turnover [letter]. *Nature* 1995, 375:194.
6. Zhang ZQ, Notermans DW, Sedgewick G, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. *Proc Natl Acad Sci USA* 1998, 95:1154-1159.
7. Mosmann T, Cherwinski H, Bond M, et al. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 1986, 136:2348-2357.

8. 藤原大美編著 T細胞の免疫学 第3版. 1997, p201-217. 中外医学社.
9. Yamamura M, Wang X-H, Ohmen JD, et al. Cytokine patterns of immunologically mediated tissue damage. *J Immunol* 1992, 149:1470-1475.
10. Maggi E, Biswas P, Del Prete GF, et al. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. *J Immunol* 1991, 146:1169-1174.
11. Parronchi P, Macchia D, Piccinni MP, et al. Allergen- and bacteria antigen-specific T-cell clones established from atopic donor show a different profile of cytokine production. *Proc Natl Acad Sci USA* 1991, 88:4538-4542.
12. Barnes PF, Lu S, Abrams JS, et al. T-cell cytokine responses in human infection with mycobacterium tuberculosis. *Infect Immunol* 1993, 61:3482-3489.
13. Haanen JB, De-Waal MR, Res PC, et al. Selection of a human T helper type 1 like T cell subset by mycobacteria. *J Exp Med* 1991, 174:583-592.
14. Hsieh CS, Macatonia SE, Ogarra A, et al. T cell genetic background determines default T helper phenotype development in vitro. *J Exp Med* 1995, 181:713-721.
15. Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. *J Clin Invest* 1993, 91: 759-765.

16. Clerici M, and Shearer GM. A TH1-TH2 switch in a critical step in the ethiology of HIV infection. *Immunol Today* 1993, 14:107-111.
17. Saag M, Autran B. The role of Immunotherapy in the treatment of HIV. *AIDS* 2001, 15:supple2.
18. 藤原大美編著 T細胞の免疫学 第3版. 1997, p305-306. 中外医学社
19. Aribia M-H B, Moire N, Metivier D, et al. IL-2 receptors in circulating natural killer cells and T lymphocytes. *J Immunol* 1989, 142:490-499.
20. Joseph A, Kovacs MD, Vogel S, et al. Controlled trial of Interleukin-2 infusion in patients infected with the human immunodeficiency virus. *N Eng J Med* 1996, 355:1350-1356.
21. Levy Y, Capitant C, Houhou S, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomized control trial. *Lancet* 1999, 353:1923-1929.
22. Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous Interleukin-2 to treat advanced human immunodeficiency virus type 1 in person with $<250/\mu\text{l}$ CD4+ T cells and undetectable plasma virus load. *J Infect Dis* 1999, 180:56-60.

23. Imami N, Hardy AD, Nelson MR, et al. Induction of HIV-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. *Clin Exp Immunol* 1999, 118:78-86.
24. Davey RT, Murphy RL, Grazizno FK, et al. Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy. *JAMA* 2000, 284:183-189.
25. Chun T-W, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. *Nat Med* 1999, 5:651-655.
26. Gilbert MS, Riddell S, Li C-R, et al. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human Cytomegalovirus. *J Virol* 1993, 67:3461-3469.
27. Marshall GS, Rabalais GP, Stout GG, et al. Antibodies to recombinant-derived glycoprotein B after natural human Cytomegalovirus infection correlate with neutralizing activity. *J Infect Dis* 1992, 165:381-384.
28. Alp NJ, Allport TD, Zanten JV, et al. Fine specificity of cellular immune responses in human to human Cytomegalovirus immediate-early 1 protein. *J Virol* 1991, 65:4812-4820.
29. Davignon JL, Castanie P, Yorke JA, Gautier N, Clement D, Davinche C. Anti-human

- cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides *in vitro*. J Virol 1996, 70:2162-2169.
30. Oka S, Nagata Y, Fujino Y, et al. CD8+ T lymphocyte counts as an adjunctive predictor of Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Intern Med 1997, 36:461-465.
 31. 南嶋洋一 対トカ' 叻似感染症 内科 1999, 84:677-681.
 32. Graziosi C, Pantaleo G, Gantt KR, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-1 infected individuals. Science 1994, 265:248-252.
 33. Westby M, Marriott JB, Guckian M, et al. Abnormal intracellular IL-2 and interferon-gamma production as HIV-1 associated markers of immune dysfunction. Clin Exp Immunol 1998, 111:257-263.
 34. Anderson, S. J., Coleclough, C. Regulation of CD4 and CD8 expression on mouse T cells: active removal from cell surface by two mechanisms. J Immunol 1993, 151:5123-5134
 35. Meyaard L, Hovenkamp E, Keet IPM, et al. Single-cell analysis of IL-4 and IFN- γ production by T cells from HIV-infected individuals: Decreased IFN- γ in the presence of preserved IL-4 production. J Immunol 1996, 157:2712-2718.
 36. Rodriguez N, Yano N, Eylar E, Yamamura Y. Mechanisms associated with defective TH1 cytokine production in HIV infection. Cell Mol Biol 1997, 43:951-958.

37. Norris S, Collins C, Doherty DG, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. *J Hepatol* 1998; 28:84-90.
38. Bonnet T, Dequae-Merchacou L, Moreau JF, et al. Increase CD3+CD4- lymphocyte in patients with AIDS and disseminated *Mycobacterium Avium-intracellular complex* infection. *Micro Infect* 1995, 1:771-776.
39. Gazzinelli RT, Bala S, Stevens R, et al. HIV infection suppresses type 1 lymphokine and IL-12 responses to *Toxoplasma gondii* but fails to inhibit the synthesis of other parasite-induced monokine. *J Immunol* 1995, 155:1565-1574.
40. Barcellini W, Rizzardi GP, Borghi MO, et al. TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. *AIDS* 1994, 8:757-762.
41. Emilie D, Fior R, Llorente L, et al. Cytokines from lymphoid organs of HIV-infected patients: production and role in the immune disequilibrium of the disease and in the development of B lymphomas. *Immunol Rev* 1994, 140:5-34.
42. Zhang M, Gong J, Lyer DV, et al. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. *J Clin* 1994, 94: 2435-2442.
44. Fan J, Bass HZ, Fahey JL. Elevated IFN- γ and decreased IL-2 gene express are associated with HIV infection. *J Immunol* 1993, 151:5031-5040.

45. Greenway A, Azad A, McPhee D. Human Immunodeficiency virus Type 1 nef protein Inhibits Activation pathway in peripheral blood mononuclear cell and T cell lines. *J Virol* 1995, 69:1842-1850.
46. Collette Y, Chang HL, Cerdan C, et al. Specific Th1 cytokine down regulation associated with primary clinically derived human Immunodeficiency virus type 1 Nef gene-induced expression. *J Immunol* 1996, 156:360-370.
47. Haraguchi S, Cianciolo GJ, Good RA, et al. Inhibition of interleukin-2 and interferon- γ by an HIV-1 Nef-encoded synthetic peptide. *AIDS* 1998, 18:820-822
48. Sakaida H, Murakami T, Kawamata S, et al. V3 loop of Human Immunodeficiency virus type 1 suppresses Interleukin-2-induced T cell growth. *AIDS Res Hum Retro* 1997, 13:151-15157.
49. Tanaka M, Hirabayashi Y, Ida S, et al. Reduction in interleukin-2-producing cells but not Th1 to Th2 shift in moderate and advanced stage of human immunodeficiency virus type-1-infection. *Scand J Immunol* 1999, 50:550-554.
50. Mohri H, Bonhoeffer S, Monard S, et al. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. *Science* 1998, 279:1223-1227.
51. Hellerstein MK. Measurement of T-cell kinetics: recent methodological advances. *Immunol Today* 1999, 20:301-327.

52. Sereti I, Herpin B, Metcalf J, et al. Apoptosis rate of T-lymphocytes in HIV patients increase during intermittent administration of interleukin-2. Seventh conference on Retrovirus and opportunistic infections 2000[Abstract 382].
53. Simonelli C, Zanussi S, Dandrea M, et al. Interleukin-2 treatment reduce soluble CD30 plasma levels and the percentage of apoptotic cell in HIV infected patients. XII International Conference on AIDS 1998[Abstract 41235].
54. Paiardini M, Galati D, Cervasi B, et al. Exogenous Interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from Human Immunodeficiency Virus-infected individuals. *J Virol* 2001, 75:10843-10855.
55. Ishii N, Takeshita T, Kimura Y, et al. Expression of the IL-2 receptor- γ chain on various population in human peripheral blood. *Inter Immunol* 1994, 6:1273-1277.
56. Perola O, Ripatti A, Pelkonen J, et al. T-lymphocyte subpopulations do not express identical combination of IL-2 receptor chains in the early phase of their activation and proliferation. *Scand J Immunol* 2000, 52:123-130.
57. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. *Blood* 2001, 98:2736-2744.
58. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25^{high} regulatory cells in human peripheral blood. *J Immunol* 2001, 167:1245-1253.

59. Annunziato F, Cosmi L, Liotta F, et al. Phenotype, Localization, and Mechanism of suppression of CD4+CD25+ Human thymocytes. *J Exp Med* 2002, 196:379-387.
60. McCune JM, Loftus R, Schmidt DK, et al. high prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. *J Clin Invest* 1998, 10:2301-2308.
61. Mier JW, Vachino G, Klempner, et al. Inhibition of interleukin-2-induced tumor necrosis factor released by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of IL-2-associated side. *Blood* 1990, 76:1933-1940.
62. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. *Ann Intern Med* 1989, 111:223-231.
63. Bowen EF, Wilson P, Atkins M, et al. Natural history of untreated cytomegalovirus retinitis. *Lancet* 1995, 346:1671-1673.
64. Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1997, 337:105-114.
65. Jouan M, Saves M, Tubiana R, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. *AIDS* 2001, 15:23-31.

66. Casado JL, Arrizabalaga J, Montes M, et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. *AIDS* 1999, 13:1497-1502.
67. Tanaka M, Yasuoka C, Oka S, et al. Sustained Cytomegalovirus-specific CD4+ T cell response associated with prevention of recurrence of cytomegalovirus retinitis without secondary prophylaxis after highly active antiretrovirus therapy in patients with AIDS. *AIDS Res Hum Retro Virus* 2001, 17:1749-1756.
68. Suni MA, Picker LJ, and Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. *J Immunol Method* 1998, 212:89-98.
69. Kurihara T, Hayashi J, Matsuoka T, et al. HCMV pp65 antigenemia assay using indirect alkaline phosphate staining method. *Biomed Res* 1995, 16:125-129.
70. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. *Science* 1992, 257:238-241.
71. Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. *Science* 1998; 279: 2103-2106.
72. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. *Science* 1997, 278:1447-1450.

73. Torigoe S, Cambell DE, Starr SE. Cytokine releases by human perepheral blood mononuclear cells inhibit the production of early and late cytomegalovirus protein. *Microbiol Immunol* 1997, 45:403-413.
74. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+T lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. *Nat Med* 1998, 4:953-956.
75. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1 specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. *Nat Med* 1999, 5: 518-525.
76. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. *Nature* 2002, 407:523-528.
77. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruption during early infection. *Science* 2000, 290:1591-1593.
78. Malhotra U, Berrey MM, Huand Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. *J infect Dis* 2000, 181:121-131.

79. Ruiz L, Martínez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. *AIDS* 2000, 14:397-403.
80. Ruiz L, Carcelain G, Martínez-Picado J, et al. HIV dynamics and T-cell immunity after three structured treatment interruption in chronic HIV-1 infection. *AIDS* 2001, 15:F19-27
81. García F, Plana M, Mestre G, et al. Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection. *AIDS* 2002, 16:1761-1765.
82. Carcelain G, Tubiana R, Mollet L, et al. Intermittent interruption of antiretroviral therapy in chronically HIV-infected patients do not induce immune control of HIV. Seventh conference on Retrovirus and opportunistic infections 2000, [Abstract 356].
83. Rosenberg ES. Preserving HIV-1 specific T-cell help: will it prevent progression? Sixth conference on Retrovirus and opportunistic infections 1999, [Abstract S41].
84. Yamaguchi S, Onji M, Ohta Y et al. Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant IL2. *Clin Exp Immunol* 1988, 74:1-6.